Table 2.
Relationship between sarcopenia and adverse effects during conversion therapy in GC-CY1 patients.
| Adverse effects | Pre-treatment | p | Post-treatment | p | ΔSMI (%)/50 days | p | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sarcopenia(n=7) | No-sarcopenia(n=29) | Sarcopenia(n=13) | No-sarcopenia(n=23) | SML(n=8) | No-SML(n=28) | |||||
| Leukopenia | ||||||||||
| Yes/No | 3/4 | 5/24 | 0.167* | 5/8 | 3/20 | 0.107* | 6/2 | 2/26 | <0.001* | |
| ≥3 grade/<3grade | 2/5 | 0/29 | 0.033* | 2/13 | 0/23 | 0.149* | 2/6 | 0/28 | 0.044* | |
| Neutropenia | ||||||||||
| Yes/No | 4/3 | 3/26 | 0.016* | 4/9 | 3/20 | 0.225* | 5/3 | 2/26 | 0.003* | |
| ≥3 grade/<3grade | 2/5 | 0/29 | 0.033* | 1/12 | 1/22 | 1.000* | 2/6 | 0/28 | 0.044* | |
| Thrombocytopenia | ||||||||||
| Yes/No | 3/4 | 1/28 | 0.018* | 4/9 | 0/23 | 0.012* | 4/4 | 0/28 | 0.001* | |
| ≥3 grade/<3grade | 0/7 | 0/29 | 1.000* | 0/13 | 0/23 | 1.000* | 0/8 | 0/28 | 1.000* | |
| Decreased hemoglobin | ||||||||||
| Yes/No | 1/6 | 0/29 | 0.194* | 1/12 | 0/23 | 0.361* | 1/7 | 0/28 | 0.222* | |
| ≥3 grade/<3grade | 0/7 | 0/29 | 1.000* | 0/13 | 0/23 | 1.000* | 0/8 | 0/28 | 1.000* | |
| Nausea/vomiting | ||||||||||
| Yes/No | 5/2 | 4/25 | 0.006* | 5/8 | 4/19 | 0.235* | 7/1 | 2/26 | <0.001* | |
| ≥3 grade/<3grade | 2/5 | 0/29 | 0.033* | 1/12 | 1/22 | 1.000* | 2/6 | 0/28 | 0.044* | |
| Diarrhea | ||||||||||
| Yes/No | 1/6 | 0/29 | 0.194* | 1/12 | 0/23 | 0.361* | 1/7 | 0/28 | 0.222* | |
| ≥3 grade/<3grade | 0/7 | 0/29 | 1.000* | 0/13 | 0/23 | 1.000* | 0/8 | 0/28 | 1.000* | |
| Anorexia | ||||||||||
| Yes/No | 2/5 | 1/28 | 0.090* | 3/10 | 0/23 | 0.040* | 3/5 | 0/28 | 0.008* | |
| ≥3 grade/<3grade | 0/7 | 0/29 | 1.000* | 0/13 | 0/23 | 1.000* | 0/8 | 0/28 | 1.000* | |
| Peripheral sensory neuropathy | ||||||||||
| Yes/No | 1/6 | 0/29 | 0.194* | 1/12 | 0/23 | 0.361* | 1/7 | 0/28 | 0.222* | |
| ≥3 grade/<3grade | 0/7 | 0/29 | 1.000* | 0/13 | 0/23 | 1.000* | 0/8 | 0/28 | 1.000* | |
| AST/ALT increased | ||||||||||
| Yes/No | 0/7 | 1/28 | 1.000* | 1/12 | 0/23 | 0.361* | 0/8 | 1/27 | 1.000* | |
| ≥3 grade/<3grade | 0/7 | 0/29 | 1.000* | 0/13 | 0/23 | 1.000* | 0/8 | 0/28 | 1.000* | |
| Proteinuria | ||||||||||
| Yes/No | 2/5 | 2/27 | 0.163* | 3/10 | 1/22 | 0.124* | 2/6 | 2/26 | 0.207* | |
| ≥3 grade/<3grade | 0/7 | 0/29 | 1.000* | 0/13 | 0/23 | 1.000* | 0/8 | 0/28 | 1.000* | |
| Oral mucositis | ||||||||||
| Yes/No | 1/6 | 0/29 | 0.194* | 0/13 | 1/22 | 1.000* | 1/7 | 0/28 | 0.222* | |
| ≥3 grade/<3grade | 0/7 | 0/29 | 1.000* | 0/13 | 0/23 | 1.000* | 0/8 | 0/28 | 1.000* | |
| Fatigue | ||||||||||
| Yes/No | 2/5 | 1/28 | 0.090* | 3/10 | 0/23 | 0.040* | 3/5 | 0/28 | 0.008* | |
| ≥3 grade/<3grade | 1/6 | 0/29 | 0.194* | 1/12 | 0/23 | 0.361* | 1/7 | 0/28 | 0.222* | |
According to Common Terminology Criteria for Adverse Events (version 3.0). AST, aspartate transaminase; ALT, alanine aminotransferase. *Fisher’s exact test.